belantamab mafodotin + isatuximab

This is an **investigational combination therapy** comprising **belantamab mafodotin**, a B-cell maturation antigen (BCMA)-directed antibody-drug conjugate (ADC), and **isatuximab**, a CD38-directed monoclonal antibody. Belantamab mafodotin targets BCMA on malignant plasma cells, delivering the cytotoxic agent monomethyl auristatin-F (MMAF), which disrupts microtubules and induces apoptosis, while also engaging immune effectors via its afucosylated Fc region to stimulate antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis. Isatuximab binds CD38 on multiple myeloma cells, promoting direct apoptosis, ADCC, complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP). The combination is under clinical investigation for relapsed or refractory multiple myeloma based on preclinical and early clinical synergy, aiming to enhance anti-myeloma efficacy by dual targeting of the myeloma cell surface antigens and engaging multiple immune effector pathways[1][2][3][4][5][6][9].

Brand names

Blenrep (for belantamab mafodotin)Sarclisa (for isatuximab)

Other names

belantamab mafodotin plus isatuximabBlenrep plus Sarclisa